<DOC>
	<DOCNO>NCT01100021</DOCNO>
	<brief_summary>The purpose study see avanafil cause change blood pressure pulse rate take doxazosin tamsulosin .</brief_summary>
	<brief_title>Hemodynamic Study Avanafil Two Î±-Adrenergic Blockers , Doxazosin Tamsulosin</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Adrenergic Antagonists</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<criteria>1 . Written Informed Consent . 2 . Adult male subject 40 65 year age , inclusive . 3 . A body weight least 50 kg body mass index ( BMI ) 18 32 kg/m2 , inclusive [ BMI calculate weight kg/ ( height ) 2 ] . 4 . Subjects able communicate Investigator , understand comply requirement study participation . 5 . Medically healthy , clinically significant screen result ( e.g. , laboratory profile , medical history , ECGs , physical exam , etc . ) , opinion Investigator consultation Sponsor . 6 . Male subject willing use condom spermicide sexual activity 90 day last dosing avanafil willing donate sperm 90 day dose . 1 . A history presence significant cardiovascular ( include thromboembolic disorder ) , neurological , hematological , psychiatric , hepatic , gastrointestinal , pulmonary , endocrine , immunologic renal disease condition know interfere absorption , distribution , metabolism , excretion drug place subject increase risk determine Investigator . 2 . Any clinically significant laboratory abnormality judge Investigator . Inclusion subject normal range laboratory value must approve VIVUS prior subject enrollment . 3 . A predisposition priapism , subject sickle cell disease blood dyscrasia . 4 . Known history cardiovascular cerebrovascular event , history angina . 5 . Subjects episode ( ) faint vasovagal hypotension . 6 . History ECG evidence highrisk arrhythmia ECG judge Investigator clinically significant . 7 . Hypertrophic obstructive clinically significant cardiomyopathy , moderate severe cardiac valvular disease . 8 . Subjects whose pulse low 55 bpm screen 50 bpm prior dose . 9 . Acute illness , especially infection , within 2 week dose . 10 . Systolic blood pressure &lt; 90 &gt; 150 mmHg ; diastolic blood pressure &lt; 50 &gt; 95 mmHg screen checkin Day 1 ( 2 rechecks allow ) . 11 . Subjects benign prostatic hyperplasia orthostatic hypotension ( evidence reduction 20 mmHg systolic blood pressure , reduction 10 mmHg diastolic blood pressure , evidence cerebral hypoperfusion upon stand seat position ) . 12 . History retinitis pigmentosa nonarteritic anterior ischemic optic neuropathy . 13 . Any history bipolar disorder psychosis , history psychiatric hospitalization , great one lifetime episode major depression . 14 . Hemoglobin &lt; 12.0 g/dL . 15 . Subjects liver function test &gt; 1.5 ULN 16 . Positive urine drug test and/or positive urine alcohol test screen checkin Day 1 . 17 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) screening . 18 . Any history presence alcoholism drug substance abuse within 18 month define Investigator . 19 . Allergy previously significant adverse event PDE5 inhibitor , doxazosin tamsulosin constituent . 20 . Use prescription overthecounter ( OTC ) medication , include herbal product , within 14 day prior Day 1 . Up 2 g per day acetaminophen allow discretion Investigator . 21 . Use drug Appendix 1 ( drug know clinical significance inhibit induce liver enzyme involve drug metabolism [ CYP P450 ] ) within 30 day prior Day 1 . 22 . Blood donation significant blood loss within 56 day prior Day 1 . 23 . Plasma donation within 14 day prior Day 1 . 24 . Any use tobacco nicotine product within 6 month prior Day 1 . Serum cotinine level &lt; 10 ng/mL consider consistent active smoking . 25 . Any subject receive investigational drug within 30 day six halflives , whichever longer , prior Day 1 . 26 . Evidence clinically significant medical , psychiatric , social condition history , physical examination laboratory study , opinion Investigator , would contraindicate administration study medication , affect compliance , interfere study evaluation , limit study participation , confound interpretation study result . 27 . Involvement plan conduct study ( applies VIVUS designee staff , staff investigational site ) . 28 . Previously participate trial avanafil .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>